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Papua New Guinea (PNG) has the highest malaria transmission outside of Africa. Long-
lasting insecticidal nets (LLINs) are believed to have helped to reduce average malaria pre-
valence in PNG from 16% in 2008 to 1% in 2014. Since 2015 malaria in PNG has resurged
significantly. Here, we present observations documenting decreased bioefficacy of unused
LLINs with manufacturing dates between 2013 and 2019 collected from villages and LLIN
distributors in PNG. Specifically, we show that of n= 167 tested LLINs manufactured after
2013, only 17% are fulfilling the required World Health Organisation bioefficacy standards of
≥ 80% 24 h mortality or ≥ 95% 60min knockdown in bioassays with pyrethroid susceptible
Anopheles farauti mosquitoes. In contrast, all (100%, n= 25) LLINs with manufacturing dates
prior to 2013 are meeting these bioefficacy standards. These results suggest that decreased
bioefficacy of LLINs is contributing to the malaria resurgence in PNG and increased scrutiny
of LLIN quality is warranted.
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Papua New Guinea accounts for over 80% of malaria cases inthe World Health Organisation (WHO) Western PacificRegion1. Long-lasting insecticidal nets (LLINs) are an
important vector-control tool in malaria endemic countries
including Papua New Guinea (PNG). Since the start of the dis-
tribution campaigns close to 2 billion LLINs have been delivered
worldwide2. The global distribution of LLINs has contributed
significantly to saving an estimated 6.8 million lives between 2000
and 20153.
In PNG, distributions started in 2006 and 12.8 million LLINs
were delivered to the country between 2010 and 2019, with about
10.2 million since 2013. LLINs are the only vector-control tool
implemented by the national malaria control program on a
nationwide level1,4. From 2006 and until the end of 2019, the
LLINs distributed within PNG were exclusively deltamethrin-
treated PermaNet® 2.0 (Vestergaard–Frandsen). Globally, Per-
maNet® 2.0 had the largest market share in the LLIN industry in
20145. Rotary Against Malaria (RAM) PNG is currently mana-
ging LLIN distribution in PNG.
Initially, LLIN distribution in PNG coincided with a massive
decrease in malaria disease burden and infection prevalence from
15.7% (2008/2009) to 4.8% (2010/2011) and <1% (2013/2014)6–8.
However, malaria indicators are on an upsurge in PNG since
2015, with a reported 9-fold increase (from <1% to 7.1%) in
prevalence between 2013/14 and 2016/179,10. The cause of this
resurgence is currently not well understood but is likely due to
multiple factors acting together. While PNG has experienced
prolonged stock outs of antimalarial drugs during 2016–2017, it
seems unlikely that drug shortages alone will lead to massive
resurgence of transmission if >80% of infections are asympto-
matic i.e. remain mostly untreated11,12. Malaria indicators also
continued to rise after shortages of drugs had finished. Vector
behavioural patterns may influence LLIN impact. In general,
PNG malaria vectors, including the main coastal vector Anopheles
farauti (An. farauti) tend to be exophagic and, with few excep-
tions, exhibit opportunistic host preference13,14. This is believed
to be detrimental to LLIN impact as most human-vector contact
occurs outside the house and vectors can easily seek alternative
hosts thereby avoiding contact with the LLINs. In addition, stu-
dies suggest behavioural adaptation of local malaria vectors to
LLINs, such that biting now occurs earlier in the evening15,16.
Continued electrification (e.g. with solar-powered lights) allows
people to be active much longer into the night than previously,
even in remote PNG communities, which may enhance human-
vector contact further. While insecticide resistance will have a
detrimental effect on LLIN bioefficacy17,18 regular insecticide
resistance monitoring activities show no signs of emerging pyr-
ethroid resistance in the anopheline mosquito populations in
PNG since the beginning of the LLIN distributions19. This stands
in contrast to recently found high levels of pyrethroid resistance
in Aedes aegypti populations in PNG20.
Reduced bioefficacy of LLINs can also be a result of sub-
standard manufacturing process and distributions of substandard
LLINs have occurred before, e.g. in Rwanda (2015) and Solomon
Islands (2014)21,22. LLINs in use for 3 years or less should exhibit
80% 24 h mortality or 95% 60min knockdown in standardised
WHO cone bioassays23,24. Studies on the bioefficacy of Perma-
Net® 2.0 in use between 2000 and 2009 in PNG conducted by
Katusele et al.25 indicated that these LLINs were still highly
effective even after 5 years of use, killing close to 100% of mos-
quitoes in standardised WHO cone bioassays. Only a slight
reduction in bioefficacy in LLINs in use for more than 7 years was
observed in these previous studies25. Similar results for Perma-
Net® 2.0 obtained in an African setting at the same time indicate
that LLINs of this brand were fulfilling and exceeding WHO
requirements during that period26.
In order to understand whether LLIN bioefficacy may be a
contributing factor to malaria resurgence in PNG, we show WHO
bioefficacy test results from n= 192 brand new PermaNet® 2.0
LLINs still in original and unopened packaging collected either
prior to distribution (for years 2018–2019) or from PNG com-
munities (for years 2007–2017). Alongside, we present data from
n= 40 used PermaNet® 2.0 LLINs collected in PNG communities.
Our results indicate that LLINs distributed in PNG between 2013
and 2019 did not meet WHO bioefficacy standards. At the same
time, PNG experienced a substantial resurgence in malaria.
Results
Cone bioassays with new LLINs. Unused LLINs normally exhibit
100% 24 h mortality to fully pyrethroid (deltamethrin) susceptible
anopheline mosquitoes25,26. Most of the new LLINs manu-
factured between 2007 and 2012 (n= 25) exhibited 100% 24 h
mortality in the cone bioassays (21/25, 84.2%). All LLINs in this
group also exhibited either ≥80% 24 h mortality or ≥95%
Table 1 Number of new and unused LLINs and number of mosquitoes tested per year of LLIN manufacture, and resulting
mosquito knockdown and mortality.
Year LLINs tested Mosquitoes tested Mosquitoes KD/deada % KD60min (95% CI)b % M24h (95% CI)c
2007 1 25 25/25 100.00 (86.28–100) 100.00 (86.28–100)
2008 3 75 69/74 92.00 (83.4–97.01) 98.67 (92.13–100)
2009 2 50 50/50 100.00 (92.89–100) 100.00 (92.89–100)
2010 7 175 173/173 98.86 (95.93–99.86) 98.86 (95.93–99.86)
2012 12 300 286/295 95.33 (92.29–97.43) 98.33 (96.15–99.46)
Sub-total (2007–2012) 25 625 603/617 96.48 (94.72–97.78) 98.72 (97.49–99.45)
2013 20 500 243/241 48.60 (44.14–53.08) 48.20 (43.74–52.68)
2014 9 225 68/65 30.22 (24.3–36.68) 28.89 (23.06–35.29)
2015 24 600 339/369 56.50 (52.43–60.51) 61.50 (57.47–65.41)
2016 11 275 90/55 32.73 (27.21–38.62) 20.00 (15.44–25.22)
2017 54 1350 395/338 29.26 (26.84–31.77) 25.04 (22.75–27.44)
2018 27 662 396/385 59.82 (55.97–63.58) 58.16 (54.29–61.95)
2019 22 550 185/217 33.64 (29.69–37.76) 39.45 (35.35–43.68)
Sub-Total (2013–2019) 167 4162 1716/1670 41.23 (39.74–42.73) 40.12 (38.65–41.62)
Overall 192 4787 2319/2287 48.44 (47–49.9) 47.78 (46.4–49.2)
Source data for this table are provided as a Source Data file.
aNumber of mosquitoes knocked down (KD) after 60min and number of mosquitoes dead after 24 h (dead).
bMean percent 60min knockdown (KD60min, bold) with exact 95% confidence intervals of the proportions (95% CIs, in parentheses).
cMean percent 24 h mortality (M24h, bold) with exact 95% confidence intervals of the proportions (95% CIs, in parentheses).
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knockdown indicating that these nets would likely have passed a
phase 3 bioefficacy study at baseline as per WHO guidelines23.
In striking contrast, of the unused LLINs manufactured
between 2013 and 2019 only 7% (12/167) exhibited 100% 24 h
mortality and the proportion of nets exhibiting either ≥80%
mortality or ≥95% knockdown reduced from 100% (95%
confidence interval (CI) 86–100%) in the 2007–2012 group to
17% (95% CI 9–20%) in the 2013–2019 group. The difference was
highly statistically significant (Chi-squared equal to 75.4; p-value
< 10−5).
Table 1 shows summary data for all new LLINs tested in the
present study grouped by the year of manufacture.
Figure 1 shows 24 h mortality rates and 60 min knockdown
rates versus year of LLIN manufacture, and correlation of these
two measures for the n= 192 unused LLINs tested in this study.
Figure 2 shows the decline in the proportion of unused LLINs
exhibiting either ≥80% 24 h mortality or ≥95% 60min knock-
down by year of manufacture. Data are also presented grouped
into 2007–2012 and 2013 to 2019 groups.
Cone bioassays with used LLINs. Table 2 shows summary data
for all used LLINs (n= 40) tested in the present study grouped by
owner-reported LLIN usage duration of either more or less than 3
years.
The proportions of mosquitoes knocked down after 60 min in
the two groups were 51% and 48%, respectively, and the
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Fig. 1 WHO cone-bioassay data for new and unused LLINs by year of
manufacture. a 60min knockdown rates of new LLINs. b Adjusted 24 h
mortality rates of new LLINs. c Correlation between 60min knockdown and
adjusted 24 h mortality rates. The dashed lines indicate 95% 60min
knockdown (a and c) and 80% 24 h mortality (b and c) rates. The colours
and symbols differentiate between 2007–2012 LLINs (turquois circles) and
2013–2019 LLINs (magenta crosses). Error bars in panels a and b are
medians and interquartile ranges (only presented for sample sizes of n≥ 7).
Each data point represents one bioassay result conducted on one individual,
independent LLIN (number of LLINs tested per year given in Table 1 in the
‘LLINs tested’ column). If the bioassay was valid (negative control mortality
<10%), bioassays on individual LLIN samples were not repeated. Source
data for this Figure are provided as a Source Data file.
a b
1 3
2007–2012 2013–2019Number of LLINs tested Number of LLINs tested
2 7 12 20 9 24 11 54 27 22 25
p<10-5
167 192
Year of LLIN manufacture
Pr
op
or
tio
n 
of
 L
LI
N 
wi
th
M
24
h>
80
%
 o
r K
D 6
0m
in
>
95
%
1.0
0.8
0.6
0.4
0.2
0.0
20
07
20
08
20
09
20
10
20
11
20
12
20
13
20
14
20
15
20
16
20
17
20
18
20
19
20
07
–2
01
2
20
13
–2
01
9
ov
er
all
Fig. 2 Proportion of new and unused LLINs with adequate bioefficacy by
year of manufacture. a Proportion of new and unused LLIN exhibiting
≥95% 60min knockdown (KD60min) or ≥80% adjusted 24 h mortality
(M24h) grouped by year of manufacture. b Proportion of LLINs exhibiting
≥95% 60min knockdown (KD60min) or ≥80% adjusted 24 h mortality
(M24h) for groups with years of manufacture between 2007–2012
(turquois circles) and from 2013 to 2019 (magenta crosses), as well as
overall (2007–2019, black circle). The table on top of the panels indicates
the numbers of individual LLINs tested in each year or group. Data are
presented as mean proportions and their exact 95% confidence intervals.
The p-value between the 2007–2012 and 2013–2019 groups is the result of
a Chi-squared test (2-sided) comparing the proportions in these two
groups. The exact z-score of the test is 8.442. Source data for this Figure
are provided as a Source Data file.
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proportions of mosquitoes dead after 24 h in the two groups were
52% and 63%, respectively. The differences between the groups
were not statistically significant.
At least 80% of used LLINs should exhibit 95% 60 min
knockdown or 80% 24 h mortality if they are less than 3 years in
use23,24. Figure 3 shows owner-reported duration of LLIN
usage versus the proportion of LLINs meeting this condition
for the n= 40 used LLINs tested in the present study.
Owner-reported LLIN usage duration was not significantly
associated with observed LLIN bioefficacy and overall 37% (95%
CI: 23–54%) of the LLINs met the performance criterion.
Confirmatory bioassays. Replicate results obtained with pyre-
throid (deltamethrin) susceptible standard An. gambiae s.s. strain
G3 corresponded well to the results obtained in PNG with An.
farauti as shown in Fig. 4 (coefficient of determination equal to
0.80) indicating that results apply to susceptible Anopheles spe-
cies in other (e.g. African) settings.
Experiments simulating LLIN container storage. Data on the
temperature distribution in the storage container over the 5-day
measurement period are presented in Supplementary Fig. 1. In
summary, temperatures away from the immediate inner ceiling
surface of the container never exceeded 40 °C during the 5-day
measurement period in the hot normal conditions of Port Mor-
esby summer (February 2019). Only at the immediate inner
surface of the top of the container temperatures over 50 °C were
measured. However, even there, temperatures remained below
50 °C for 94% of the measurement period. In corresponding
experiments simulating container storage, we did not observe any
reduction in 24 h mortality or 60 min knockdown rate when
LLINs with a confirmed 100% 24 h mortality (manufacture year
2012) were exposed to 6 weeks of storage at 60 °C.
Discussion
Our findings show that LLINs distributed in PNG between 2013
and 2019 have not been exhibiting the required bioefficacy prior
to use, whereas LLINs distributed before 2013 performed sig-
nificantly better25. This observation coincides with a substantial
resurgence of malaria in many parts of the country1,9,10.
Specifically, all LLINs tested in the present study that were
manufactured between 2007 and 2012 (n= 25) exhibited either
≥80% 24 h mortality or ≥95% 60min knockdown. In contrast,
only 17% of LLINs (n= 167) that were manufactured between
Table 2 Summary of the number of LLINs and number of mosquitoes tested according to owner-reported usage duration.
Owner-reported usage duration LLINs tested Mosquitoes tested Mosquitoes KD/deada % KD60min
(95% CI)b
% M24h
(95% CI)c
1–3 years 14 280 143/135 51.07 (45.05–57.07) 48.21 (42.23–54.24)
>3 years 26 531 278/335 52.35 (48.01–56.67) 63.09 (58.83–67.20)
Overall 40 811 421/470 51.91 (48.41–55.40) 57.95 (54.47–61.38)
Source data for this table are provided as a Source Data file.
aNumber of mosquitoes knocked down (KD) after 60min and number of mosquitoes dead after 24 h (dead).
bMean percent 60min knockdown (KD60min, bold) with exact 95% confidence intervals of the proportions (95% CIs, in parentheses).
cMean percent 24 h mortality (M24h, bold) with exact 95% confidence intervals of the proportions (95% CIs, in parentheses).
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Fig. 3 Bioefficacy of used LLINs. a Owner-reported LLIN usage duration
versus the proportion of LLINs with either ≥95% 60min knockdown
(KD60min) or ≥80% 24 h mosquito mortality (M24h). Data are presented as
mean proportions and their exact 95% confidence intervals. Data from
LLINs with years of manufacture between 2007–2012 are presented as
turquois circles and from 2013 to 2019 as magenta crosses. Overall data
(2007–2019) is presented as black circle. The table on top of the panels
indicates the numbers of individual LLINs tested in each year or group. b
KD60min versus adjusted M24h for all used LLINs tested (n= 40). The
dashed lines indicate 95% KD60min and 80% M24h thresholds. Each data
point represents one bioassay result conducted on one individual,
independent LLIN. If the bioassay was valid (positive and negative control
mortality <10%), bioassays on individual LLIN samples were not repeated.
Source data for this Figure are provided as a Source Data file.
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Fig. 4 Correlation of cone-bioassay data (24 h mortality) for An. farauti
and An. gambiae G3. Experiments with An. farauti were conducted at
PNGIMR and experiments with An. gambiae G3 were conducted at LSTM
with using the same LLIN samples (n= 19). The best fit curve obtained
using standard linear regression analysis is represented by the continuous
black line. The grey shading in between the dotted lines represents the 95%
confidence band of the best fit curve. Each data point represents one
bioassay result conducted on one individual, independent LLIN. If the
bioassay was valid (positive and negative control mortality <10%)
bioassays on individual LLIN samples were not repeated. Source data for
this Figure are provided as a Source Data file.
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2013 and 2019 met these criteria. However, all LLINs should meet
these criteria.
These results span 78 separate LLIN batches. Results from 2013
indicate that some LLIN batches in that year were still performing
as expected. Specifically, batch # 1 258 13 (3) from which n= 5
LLINs were tested, exhibited 100% knockdown and 100% mor-
tality for all five of these LLINs. The other five LLIN batches
tested from 2013 all exhibited diminished bioefficacy. After 2013,
none of the batches from which multiple LLINs were available
exhibited bioefficacy results meeting aforementioned criteria for
all LLINs sampled from a specific batch. This indicates that the
change occurred in 2013.
Although the number of LLIN tested for the 2007–2012 period
is relatively small due to the difficulty of obtaining unused LLINs
from such a long time ago, the difference observed between the
2007–2012 and the 2013–2019 groups is large and statistically
significant (Chi-squared equal to 75.4; p-value < 10−5;
z-score 8.4).
We adhered strictly to WHO guidelines in terms of cone-
bioassay setup and conditions. However, since this was a
research study involving a registered and certified product,
rather than a phase 3 trial aimed at obtaining WHO certifica-
tion for a new product, less mosquitoes per individual LLIN
were exposed. Specifically, in a phase 3 LLIN trial, usually five
sections from 30 unused LLINs are tested with 20 mosquitoes
each, resulting in 100 exposed mosquitoes per LLIN and a total
of 3000 exposed mosquitoes per study23. Operational mon-
itoring guidelines recommend exposure of 40 mosquitoes per
LLIN and a total of 30 LLINs to be tested, resulting in a total of
1200 mosquitoes exposed24. In the present study, we aimed to
test as many unused LLIN from previous years as possible
resulting in bioefficacy tests on n= 192 LLINs from n= 78
batches across 12 years. This is much more than would nor-
mally be tested in a phase 3 LLIN trial at baseline. However, we
tested only one section per LLIN using 25 mosquitoes, resulting
in 4787 mosquitoes exposed to LLINs in cone bioassays. This
study has the limitation that we did not account for within-
LLIN variability in our analyses. However, we have sampled
from a very broad range of LLINs, exposing a large number of
susceptible mosquitoes, resulting in overwhelmingly statisti-
cally significant results. Thus, while testing multiple sections
per LLIN in the precertification phase is important to ensure
product quality, it is of less relevance to the conclusions of this
study with regards to the diminished bioefficacy of a large
number of unused LLINs. For further confirmation, we tested
n= 5 sections (four sides+ roof) from one net from each of
the years 2007, 2008, 2009, 2010 and 2012 with 20 mosquitoes
each. All 25 of these bioassays showed 100% 60 min knockdown
and 100% 24 h mortality.
Since used LLINs may be subject to more wear on the side
panels than on the roof, our methodology may have resulted in an
overestimation of the used LLINs failing the ≥80% 24 h mortality
or ≥95% 60min knockdown criteria for the used LLIN category,
which is a limitation of this study.
PermaNet® 2.0 has been among the most widely distributed
LLIN brand in the recent decade and bioefficacy studies have
been conducted in several countries. Most of these studies used
LLINs dating back to 2012 and before, and showed very good
bioefficacy of PermaNet® 2.027–31. In tests conducted in an
African setting (Northern Tanzania), PermaNet® 2.0 from 2017
were reported to fulfil all requirements32. However in a recent
report from Iran, PermaNet® 2.0 did not seem to fulfil bioeffi-
cacy requirements33. Studies also investigated the effect of
developing pyrethroid resistance on PermaNet® 2.0 bioefficacy,
e.g. refs. 17,34. Unsurprisingly, pyrethroid resistance reduced the
knockdown and mortality rates of the exposed mosquitoes.
While storage at elevated temperatures could potentially be
detrimental to LLIN bioefficacy (we are not aware of published
evidence for this), we consider it unlikely that this is responsible
for the diminished bioefficacy of the LLINs as observed in the
present study. Firstly, the n= 25 LLINs manufactured between
2007 and 2012 (obtained from several different provinces and 19
different production batches) tested in this study had been stored
in tropical climate for up to 12 years before testing. All 25 of these
LLINs exhibited either ≥80% 24 h mortality or ≥95% 60min
knockdown. Secondly, all samples of unused LLINs in their ori-
ginal and unopened packaging from 2018 and 2019 were taken
from the coolest, most central parts of the containers where
temperatures do not appear to exceed 40 °C (temperature data
from an LLIN container in Port Moresby can be found in Sup-
plementary Fig. 1). Thirdly, our experiments where LLINs from
2012 (confirmed 100% 24 h mortality) were exposed to 6 weeks
storage at 60 °C showed no signs of reduced 24 h mortality or
60 min knockdown rate when tested with susceptible An. farauti
mosquitoes.
It has been noted that the manufacturer made structural
changes to the LLINs over the years. Bails of 100 LLINs weighing
50 kg in 2012 weighed as little as 43 kg in 2019, which translates
to a weight reduction of 70 g per net. While these changes may be
explained in terms of changing knitting weave, it calls into
question if other changes have taken place and whether these
LLINs have consequently been tested again to confirm bioefficacy
(information on average weight of LLIN bails vs year of manu-
facture can be found in Supplementary Fig. 2).
All LLINs distributed in PNG undergo quality assurance pro-
cedures that include chemical insecticide content validation and,
in recent years, wash tests. These procedures are conducted by
Crown Agents and TÜV SÜD. Insecticide content and wash
index for the LLIN consignments in the present study were
reported to be within the prescribed ranges by these agencies
throughout the period of 2007–2019. A hypothesis arising from
this is that, while the LLINs may have the full concentration of
insecticide, the availability of insecticide may be restricted on the
surface of the LLINs. However, it appears that these predelivery
inspections provide little information about bioefficacy. There-
fore, bioefficacy testing should be included in the predelivery
inspections.
Our findings suggest that only a small proportion of Perma-
Net® 2.0 LLINs distributed in PNG in recent years met quality
standards with respect to bioefficacy, and that LLINs with
reduced and highly variable bioefficacy were distributed since at
least 2013. This may have seriously affected malaria control
efforts in the country, and it is not unlikely that other countries
may have been affected as well.
The most recent malaria indicator survey in PNG dates back to
2016 and 2017 and has reported a massive increase in malaria
prevalence in PNG from <1% to 7.1%10. These results are cor-
roborated by a rising number of clinical cases reported from
many parts of the country1. While it is not possible to unequi-
vocally attribute the coincidental rise in malaria cases over the
same period in PNG to the observations presented in this study,
we consider it highly likely that reduced bioefficacy of the LLINs
is at least in part responsible for this malaria resurgence (likely in
addition to the drug shortages and behavioural changes in mos-
quitoes and humans described above). An additional negative
effect of exposure to sublethal concentrations of insecticide on the
LLINs is that the chances for the emergence of insecticide resis-
tance may be increased35.
Few countries seem to conduct regular quality control of LLINs
received for distribution using cone bioassays36. Our present
study suggests that it may be of benefit to recipient countries to
implement this type of quality assessment to prevent distribution
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of LLINs with compromised bioefficacy and thus reduced utility
for malaria control. To investigate whether the observed problem
is restricted to PNG or if other countries and LLIN products are
also affected, we recommend that quality assurance through
operational monitoring of LLINs in all malaria endemic countries
is conducted and capacity of endemic countries to conduct the
required studies is strengthened.
Due to the widespread pyrethroid resistance in many countries,
access to insectary facilities and susceptible mosquito strains is
required to perform these tests. Further studies are required to
determine the underlying cause of the observed reduced bioeffi-
cacy of these LLINs.
Methods
Origin of tested LLINs. Unused LLINs manufactured in 2018 and 2019 (n= 49)
were provided by RAM PNG from consignments dedicated to different PNG
provinces, whereas unused LLINs manufactured in 2007–2017 (n= 143) were
obtained from villages or provincial health authorities in various PNG provinces.
All LLINs were still in original and unopened packaging,
Overall, n= 192 unused LLINs with 78 different batch numbers were tested.
These had been distributed to or were intended for distribution in 15 PNG
Provinces, namely Central, Chimbu, East New Britain, East Sepik, Eastern
Highlands, Gulf, Hela, Manus, Morobe, New Ireland, Oro, Southern Highlands,
Western, Western Highlands and West New Britain (details are provided in
Supplementary Table 1).
Used LLINs (n= 40) were collected in communities in Madang Province and
Gulf Province in 2018 and 2019, and owners were asked to indicate how long they
had been using these LLINs. These LLINs showed signs of wear and were not in
original packaging.
Temperature in storage shipping containers containing LLINs. Temperature
was logged over a period of 5 days in four locations in a shipping container filled
with LLIN in Port Moresby. Temperature loggers (USB Data Logger RC5, Elitech)
were placed into four locations inside the container (i) immediately beneath the
ceiling; (ii) in the centre of the topmost layer of LLIN bails; (iii) immediately
beneath the topmost layer of LLIN bails; (iv) in the centre of the container.
To simulate container storage at elevated temperatures, n= 3 LLINs with
confirmed 100% bioefficacy (manufacture date 2012) were exposed to a
temperature of 60 °C in an oven for 6 weeks and bioefficacy was tested weekly.
Origin of exposed mosquitoes. Mosquitoes used in this study were either drawn
from a mosquito colony established at PNGIMR or collected locally as larvae and
reared to adult stage. Specifically, the laboratory colony used in the present study
was an An. farauti strain originally from Rabaul, East New Britain province, PNG.
This colony has existed for many decades and was back-crossed with local An.
farauti mosquitoes from Madang province in PNG several times, the last time in
2012. Regular WHO-tube testing on the colony mosquitoes before, throughout and
after completion of this study confirmed susceptibility to deltamethrin, lambda-
cyhalothrin, dichlorodiphenyltrichloroethane (DDT), bendiocarb and malathion
insecticides. Local wild-caught An. farauti mosquitoes used in this study originated
from larval collections along the North Coast of Madang Province, PNG. Extensive
insecticide resistance monitoring using WHO-tube assays was conducted prior to,
during and after this study and with larvae collected from the same habitats,
confirming full susceptibility of these wild-caught mosquitoes to deltamethrin,
lambda-cyhalothrin, DDT, Bendiocarb and Malathion insecticides. Overall, there is
no indication of pyrethroid, and especially deltamethrin, resistance in Anopheline
populations from anywhere in PNG19.
WHO cone bioassays. WHO cone bioassays were conducted on the LLINs
according to WHO guidelines23,24, using 25 (as recommended in ref. 37) fully
pyrethroid susceptible An. farauti mosquitoes.
The experimental setup of the WHO cone bioassays is shown in Supplementary
Fig. 3.
Mosquitoes were 3–5-days-old when used in the cone bioassays. Tests were
conducted in ambient tropical environment (Madang, PNG, latitude 5° South), and
temperature and humidity requirements were met in all assays included in the
study. The number of mosquitoes per cone was n= 5 and exposure time to the
LLINs was 3 min.
All cone bioassays included positive and negative controls. We used LLINs
manufactured in 2012 and with a known 100% 24 h mortality as positive controls
and pieces of untreated netting as negative controls. Results were excluded if 24 h
mortality in the negative control exceeded 10%. Test results were adjusted using
‘Abbott’s formula’ when negative control 24 h mortality was >0% and ≤10%.
After exposure to the LLINs, mosquitoes were gently transferred from the
cones to cardboard holding cups screened with untreated netting and provided
access to 10% sugar solution via a soaked piece of cotton wool placed on top of
the netting. After 60 min, the number of mosquitoes knocked down in the
holding cups was enumerated and after 24 h, the number of dead mosquitoes in
the holding cups was enumerated.
The total number of mosquitoes exposed to each of the 192 unused LLIN
sections was n= 25 in five cones and the number of mosquitoes exposed to each of
the 40 used LLIN sections was n= 20 in four cones. One LLIN side panel section
(30 × 30 cm) was tested per LLIN as shown in Supplementary Fig. 3, placing the
cones onto different parts of the section. This approach used a lower number of
mosquitoes per LLIN as recommended in the WHO guidelines for large scale
(phase 3) LLIN candidate product evaluation where n= 5 sections from n= 30
unused LLINs are tested with n= 20 mosquitoes each (i.e. n= 100 mosquitos per
LLIN) and resembled more closely the approaches recommended for testing LLINs
under operational conditions24 The reason we chose this different approach is that
we aimed to test a much larger number of LLIN samples from an already WHO
certified product to span as many years and batches as possible.
Of the LLINs tested, n= 19 (including one positive and one negative control)
were sent to Liverpool School of Tropical Medicine (LSTM) for confirmation of
results through blinded repetition of the WHO cone bioassays with a very similar
Standard Operating Procedure based on WHO guidelines and the An. gambiae
G3 standard pyrethroid susceptible laboratory strain. The LSTM laboratory used
n= 50 mosquitoes (10 cones) per LLIN sample to conduct the repetitions.
Data analysis and statistics. Data were collected using the Epicollect 5 (Imperial
College, London) open access electronic data capture system. Data were analysed
using Microsoft Excel 2016 (Microsoft Inc.) and GraphPad Prism 8.0 (GraphPad
Software). No custom computer code was used.
The main outcome variables of WHO cone bioassays are 24 h mosquito
mortality and 60 min mosquito knockdown. Specifically, an LLIN should exhibit
either ≥80% 24 h mosquito mortality or ≥95% 60 min mosquito knockdown. These
are proportions and as such, wherever appropriate, exact 95% confidence intervals
of proportions (Clopper–Pearson) were used to quantify the uncertainty in a
proportion estimate due to sample size38. To summarize proportion data (e.g.
Fig. 1), medians and interquartile ranges are used. For correlation data (e.g. Fig. 4)
we used parametric correlation statistics (Pearson) and linear regression, also
depicting the 95% confidence bands of the best fit curve. This is appropriate since
even though the data presented originate from inherently non-normal distributions
they are continuous, paired and exhibit equal variances.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Figures 1, 3 and 4 contain raw data. All data collected in this study are available in the
form of an excel spreadsheet provided as Supplementary Data 1 or under https://doi.org/
10.6084/m9.figshare.12552137.v1. Source data are provided with this paper.
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